BRAF and neoplasm: While the majority (around 80%) of BRAF-mutant melanomas display some degree of tumor regression upon initial treatment with BRAF or MEK inhibitors, approximately 50% fail to meet threshold criteria for partial response and only 2–3% respond completely, implying a degree of intrinsic resistance in the majority of BRAF-mutant melanomas (2, 3, 6).